ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for ADMA Biologics, Inc. (ADMA)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | Zacks Investment Research
3 days ago | GlobeNewsWire
4 days ago | GlobeNewsWire
6 days ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | Zacks Investment Research
3 months ago | Benzinga
3 months ago | GlobeNewsWire
3 months ago | Benzinga
3 months ago | Zacks Investment Research